2024-03-29T00:24:26Z
http://repoint.unil.ch/oaiprovider/
oai:serval.unil.ch:BIB_07D092E4020F
2024-03-23T01:49:02Z
serval:BIB_07D092E4020F
First experience of durable cytoreduction in chronic lymphoid leukemia with (177)Lu-DOTATATE.
10.1007/s12032-019-1266-0
000462937600003
30919094
Savovic
T.
author
Prior
J.O.
author
Nicod-Lalonde
M.
author
Bressoud
A.
author
Roux
S.
author
Schaefer
N.
author
Meyer
M.
author
article
casereport
2019-03-27
Medical oncology
1559-131X
1357-0560
journal
36
5
41
Aged
Antineoplastic Agents/therapeutic use
Cytoreduction Surgical Procedures/methods
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Humans
Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell/pathology
Liver Neoplasms/drug therapy
Liver Neoplasms/radiotherapy
Liver Neoplasms/secondary
Neuroendocrine Tumors/drug therapy
Neuroendocrine Tumors/radiotherapy
Neuroendocrine Tumors/secondary
Octreotide/analogs & derivatives
Octreotide/therapeutic use
Organometallic Compounds/therapeutic use
Treatment Outcome
117Lu-DOTATATE
Chronic lymphoid leukemia
Neuroendocrine tumor
PET/CT
PRRT
eng
60_published
peer-reviewed
Publication types: Case Reports ; Journal Article
Publication Status: epublish